Summary and conclusions A simple scheme of investigation and treatment to restore fertility in amenorrhoeic women is described. Fifty-nine patients with amenorrhoea not due to primary ovarian failure were treated variously as appropriate, mainly with clomiphene (25), bromocriptine (15), or human menopausal gonadotrophins (12), and six by diet to increase their weight. All ovulated, and by the end of the study 55 (93 %) had conceived, 42 (71%) had delivered at least one surviving child, and five others (8%) were pregnant and awaiting delivery. Conception rates were 49% within two cycles of treatment and 66% within three cycles; using the life-table method to standardise the cumulative conception rates by correcting for patients who did not continue as long as others in the study, the expected conception rate was 79% in six cycles, 94% in 12 cycles, and 98% after 16 cycles. The multiple pregnancy rate was 13% and abortion rate 22%. Delivery rates (for a viable baby) were 48% within 11 months of starting treatment and 53% within one year; expected rates were 76% in 18 months and 97% in two years.
Introduction
Advances in our understanding of the physiology of ovulation, together with the ready availability of direct measurements of circulating hormone concentrations and effective methods to induce ovulation, have revolutionised the prognosis for fertility in anovulatory patients. Until recently treatment was largely empirical and resulted in disappointing conception rates, but a diagnosis with accurate therapeutic implications can now be reached in most patients.' We report on the results of treatment of anovulatory infertility associated with amenorrhoea in 59 patients. Choice of treatment in each case was based on our treatment-orientated diagnostic classification of amenorrhoea.2 The results are presented as cumulative rates of conception and delivery of a live baby to allow comparison with rates of fecundity in the normal population.
Patients and methods
Secondary amenorrhoea was diagnosed when the time that had elapsed since the last menstrual period equalled or exceeded six months. Primary amenorrhoea was diagnosed when menstrual bleeding had not occurred by the age of 16. In these cases the age of 16 was used as the reference point to calculate the duration of amenorrhoea.
In all patients a careful history was taken, with emphasis on psychological factors, weight fluctuations, use of prolactinergic drugs, and symptoms of thyroid disorder and a general and pelvic examination was performed. A blood sample was taken for measurement of serum follicle-stimulating hormone (FSH) and prolactin concentrations and radiography of the skull was performed. Patients were then given medroxyprogesterone acetate (Provera) 5 mg/day for five days followed one week later by clomiphene (Clomid) 50-100 mg/day for five days. Patients who menstruated normally after the progestogen challenge took clomiphene 50 mg/day for five days, and those who did not menstruate or who bled scantily (usually for only one to two days, but this was decided by the patient) took 100 mg/day. Twelve days after finishing the course of clomiphene (that is, four weeks after tests had begun) a blood sample was taken for measurement of serum progesterone concentration. If pregnancy did not occur a serum progesterone concentration of at least 30 nmol/l (10 ,Lg/l) in the midluteal phase was used as the criterion for ovulation (after clomiphene or any other later treatment).
Management of patients who did not become pregnant after the first (diagnostic) course of clomiphene was based on the results of the above-mentioned tests. In patients with raised concentrations of serum FSH (usually with oestrogen deficiency, as shown by failure to bleed after progestogen challenge) primary ovarian failure was diagnosed. This was usually confirmed by laparoscopy or, when obvious dysgenesis was absent, by biopsy of an ovarian specimen taken at laparotomy. Patients with primary ovarian failure were told of the diagnosis, and induction of ovulation was not attempted. Patients with hyperprolactinaemia were managed as we have described elsewhere.' A radiologically demonstrable tumour was usually treated by irradiation or surgery. Bromocriptine (Parlodel), given to reduce prolactin concentrations to normal, was withdrawn as soon as pregnancy was confirmed.
Patients who ovulated in response to clomiphene were given this drug as definitive treatment (50-100 mg/day, days two to six of menstruation). Patients other four patients who defaulted went abroad before treatment could begin and were lost to follow-up. Table II shows the distribution of diagnoses in the remaining 59 patients and the definitive treatment they received. Only three patients had primary amenorrhoea. This was due to hyperprolactinaemia in one patient aged 41 years and hypogonadotrophic hypogonadism associated with hyposmia in two. These two patients and one who had panhypopituitarism after surgery for a pituitary tumour were the only patients in whom the causes of hypogonadotrophic hypogonadism were organic. The median serum prolactin concentration in the patients with hyperprolactinaemia was 34 Ftg/l (range 17-130 tLg/l). In four of them pituitary tumours were detected radiologically: two received external irradiation before treatment with bromocriptine; transethmoidal adenectomy alone was completely successful in another; and the fourth was given bromocriptine as primary treatment. Six patients with hypothalamic amenorrhoea (who would otherwise have required HMG) were treated by dietary measures to increase their weight. Two later required clomiphene to correct luteal deficiency when menstruation had resumed. long (fig 1) .
Delivery rates are rarely mentioned in reports of ovulationinduction treatment. In Lunenfeld and Insler's series" 5200 of patients in their more favourable amenorrhoeic group who were treated with gonadotrophins delivered a surviving infant. In our series 710/0 (42 out of 59) already had at least one surviving baby and another 800 (five patients) were shortly expecting to deliver. The delivery rate was 530°within one year of starting treatment, and we expect 76°, to have succeeded within 18 months and 97°0 within two years (fig 3) . The multiple pregnancy rate (13°' ) is accounted for entirely by treatment with gonadotrophins (330o of those so treated) and clomiphene (12%). These rates are not significantly different from those generally reported for gonadotrophin treatment (28°; P 0-44; Lunenfeld and Insler"3) and for clomiphene (7 5% ; P =028; Merrell"). The spontaneous BRITISH MEDICAL JOURNAL 12 MAY 1979 abortion rate of 2200 is similar to that generally reported in pregnancies resulting from treatment with gonadotrophins (14-31O%13) or with clomiphene (200%"'l).
We have emphasised the importance of recognising weight loss as a cause of amenorrhoea because restoration of weight alone through dietary measures can result in spontaneous ovulation5 and thus avoids the need for treatment with HMG and its attendant risks (clomiphene is seldom effective in these patients). Many of these patients are psychologically disturbed, and of the 13 in this series, six had the typical psychopathy of chronic anorexia nervosa.' 7 Collaborative treatment with psychiatrists may be necessary but many patients resist it. These patients often present the clinician with a difficult problem when requesting induction of ovulation because of concern for the psychological welfare of the offspring. ' Think again, too, about singlehanded practice. I realise that most of you will have already dismissed the idea, but it does have the advantage that you can organise your work in a way that is impossible if you join a partnership. If you want to problemorient the records or do some research no one can stop you. If you want to use A4 records or buy a computer you have no one to convince but your bank manager. If there are other small practices in the area you can make a rota and have as much time off as in larger practices. If the area grows you may be able to take on a partner. For singlehanded practices one applies to the family practitioner committee and is interviewed by them and the medical practices committee.
Undoubtedly the place for finding a practice is the BMJ, and you should start reading the advertisements at least 18 months in advance. This has several advantages. Firstly, it gives you an idea of what is available. Thus, if you are looking for a practice in a specific area or a practice with a research interest you will get an idea of how often such vacancies occur. You will also get some idea of the kind of salaries offered and time to parity, and generally you will learn to "read between the lines." A few practices may advertise vacancies a long time in advance and these you will miss if you wait till the last minute.
If you already know where you want to settle, then in addition to reading the advertisements you should put our "feelers" in the area by asking general practitioner or consultant friends to recommend you if they hear of a practice with a vacancy for a partner. If a practice can find a partner by personal contact then they may not even advertise the post. The administrator of the local family practitioner committee may also know of coming vacancies.
